bupropion / Generic mfg. - LARVOL DELTA

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Completed

Trial completion

Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map. (PubMed, Addiction) - "Meta-analyses of electronic cigarettes (EC) for smoking cessation report point estimates favouring higher ≥6-month smoking cessation rates with nicotine EC compared with nicotine replacement therapy, non-nicotine EC/placebo, behavioural or no support and mixed support. Evidence on serious adverse events (SAEs) remains inconclusive. Evidence gaps were identified in SAE data and in studies from low- and middle-income countries."

Journal • Review • Lung Cancer • Oncology • Solid Tumor • Tobacco Cessation

Pharmacological modulation of anxiety‑like and depression‑like behaviors in nerve‑ligated mice: regarding the effects of citicoline and bupropion. (PubMed, Acta Neurobiol Exp (Wars)) - "Additionally, we determined an additive effect between bupropion and citicoline on the generation of anxiolytic and antidepressant‑like behaviors in the nerve‑ligated mice. Based on these results, we concluded that there is a crosstalk between bupropion and citicoline in the control of anxiety‑ and depression‑like behaviors in the nerve‑ligated mice."

Journal • Preclinical • CNS Disorders • Depression • Neuralgia • Pain • Psychiatry

Drugs for dementia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

Protective effect of concurrent bupropion and citicoline treatment on lipopolysaccharide-induced depression- and anxiety-like behavior in mice: The role of neuroinflammation. (PubMed, Exp Clin Psychopharmacol) - "Citicoline appears to positively potentiate bupropion's efficacy against depression- and anxiety-like behaviors in preclinical models of these human disorders, at least in part through attenuation of neuroinflammatory and oxidative processes. These findings suggest a promising experimental strategy that may help guide future clinical studies, particularly for unresponsive individuals."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Mood Disorders • Oncology • Psychiatry • IL1B • TNFA

Co-Administration Treatment in Drug-Naïve Major Depression: Exploratory Real-World Patterns and Predictors in China. (PubMed, Neuropsychiatr Dis Treat) - "The most prescribed adjunctive antidepressants were SNRIs, NaSSAs, bupropion, and trazodone; the most common antipsychotics were quetiapine, olanzapine, aripiprazole, and risperidone...This practice appears to be a symptom-driven approach, targeting specific features like sympathetic arousal and leaden paralysis, which may reflect a pragmatic adaptation to local clinical realities beyond standard guidelines. Due to exploratory nature of the study, these findings are just hypothesis-generating, warranting further validation through more robust, longitudinal studies."

Journal • Real-world evidence • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Successful Treatment of Severe Bupropion Overdose Using Plasma Exchange and Lipid Emulsion Therapy (SCCM 2026) - "Introduction: The use of ECMO, lipid emulsion therapy (LE), and plasma exchange (PLEX) for massive bupropion XL (BUP) overdose has been described in case reports and series focusing on outcomes. Assuming urine concentrations decrease proportionally to serum, this would exceed expected elimination without extracorporeal clearance. This is the first reported case demonstrating LE paired with PLEX can markedly reduce BUP half-life and lead to rapid hemodynamic and neurologic recovery."

Cardiovascular • Cough • Hypotension • Respiratory Diseases

Are They Truly Brain Dead?! A Case of Baclofen Toxicity Mimicking Brain Death (SCCM 2026) - "Toxicologic mimics of brain death can include baclofen, bupropion, tricyclic antidepressants, and barbiturates.Description: A 55-year-old female was found unresponsive with a suicide note and an empty bottle of Baclofen. In the clinical setting of brain death suspicion, it is important to take sufficient history, perform a thorough physical examination and follow proposed criteria before confirmation. This ensures minimizing unnecessary confirmatory tests as well."

Clinical • CNS Disorders • Depression • Epilepsy • Hypotension

Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Completed

Trial completion

Targeting Dopaminergic Pathways: Current and Emerging Dopamine Inhibitors in Neurological and Psychiatric Disorders. (PubMed, CNS Neurol Disord Drug Targets) - "Typical and atypical antipsychotics are essential in the treatment of schizophrenia, dopamine transporter inhibitors such as methylphenidate are firstline in ADHD, and monoamine oxidase inhibitors play a key role in Parkinson's disease. In addition, dopaminergic modulation provides adjunctive benefits through agents like bupropion...Although dopaminergic agents offer therapeutic benefits, limitations such as side effects and poor receptor selectivity persist. Emerging strategies, including targeted delivery and personalized treatment approaches, hold promise for improving efficacy and tolerability in dopaminergic therapy."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mental Retardation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia

Antidepressants and bleeding risk: Expert consensus from the Association of Medicine and Psychiatry. (PubMed, J Psychosom Res) - "The proposed algorithm can aid clinicians in determining whether antidepressant (including SRI) initiation, discontinuation, or dose adjustment should be considered for patients susceptible to bleeding. These guidelines preserve a role for clinical judgment in selection of treatments that balance the risks and benefits, which may be particularly relevant for patients with complex medical and psychiatric comorbidities. Additional studies are needed to better guide clinical decision making."

Journal • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Hematological Disorders • Psychiatry

Bupropion in Treating Comorbid Depression and ADHD: Clinical Efficacy, Considerations, and Case Insights. (PubMed, Issues Ment Health Nurs) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Hallucinations during bipolar depressive episode treated with bupropion after alcohol withdrawal surgery: a case report. (PubMed, Front Psychiatry) - "After discharge, no further bupropion was used, and the patient remained symptom-free at a one-month follow-up. This case suggests that bupropion may trigger delirium in AUD patients with a history of alcohol withdrawal surgery, underscoring the importance of careful medication selection and personalized treatment in complex cases."

Journal • Addiction (Opioid and Alcohol) • Bipolar Disorder • CNS Disorders • Depression • Mental Retardation • Psychiatry

Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2017-2023. (PubMed, Natl Vital Stat Rep) - "Among drug overdose deaths with mention of at least one specific drug, the most frequently mentioned drugs during 2017-2023 included: fentanyl, heroin, oxycodone, morphine, methadone, hydrocodone, alprazolam, diphenhydramine, cocaine, methamphetamine, amphetamine, gabapentin, and xylazine. In 2023, the most frequently mentioned drugs in unintentional drug overdose deaths were fentanyl, methamphetamine, and cocaine, while the most frequently mentioned drugs for suicide-related drug overdoses were diphenhydramine, oxycodone, and bupropion. This report identifies patterns in the specific drugs most frequently involved in drug overdose deaths from 2017 through 2023."

Journal

Off-Label Medications and Non-Invasive Brain Stimulation (NIBS) in the Treatment of Internet Gaming Disorder: A Systematic Review and Meta-Analysis. (PubMed, Addict Behav Rep) - "The findings indicated that: (i) treatment using non-invasive neuromodulation (tDCS targeting dorsolateral prefrontal cortex [DLPFC]), bupropion, selective serotonin reuptake inhibitors (SSRIs), and methylphenidate were significant in reducing IGD; (ii) pharmacotherapy was much more effective than tDCS; (iii) there were no significant differences between tDCS, SSRIs, and methylphenidate, and all except SSRIs were outperformed by bupropion; (iv) the effect of tDCS, bupropion, and SSRIs were independent of IGD severity; (v) the effect of bupropion was independent of treatment duration, gaming level, or comorbidity with depression; (vi) the effect of bupropion remained stable after 12 weeks follow-up; (vii) the effect of methylphenidate was independent of treatment duration; and (viii) the effect of SSRIs was independent of IGD severity and treatment duration. However, this initial evidence is limited in its generalizability due to high risk of bias, overrepresentation..."

Journal • Retrospective data • Review • Addiction (Opioid and Alcohol) • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Major Depressive Disorder • Psychiatry

Dextromethorphan-bupropion combination in depression with dual diagnosis: Insights from a case series. (PubMed, Indian J Psychiatry) - "We present three male patients with alcohol or opioid dependence and depression who showed substantial improvement in depressive symptoms and functioning with dextromethorphan-bupropion after multiple failed antidepressant trials. These findings highlight the clinical implications of dextromethorphan-bupropion in dual-diagnosis depression and warrant further controlled studies to establish efficacy and safety."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Helsinki University Central Hospital | Not yet recruiting ➔ Completed

Trial completion • Congestive Heart Failure

Bupropion Interference with DaT Scan Accuracy: A Case of a False Positive Diagnosis of Parkinson's Disease (AAN 2026) - " A 47-year-old man with major depressive disorder, treated with bupropion XL 450 mg daily, and mild bilateral hand action tremors since his youth, presented with new onset left hand and leg rest tremor. A medication hold duration of five elimination half-lives (8 days) may be insufficient for avoiding bupropion interference in the accuracy of Ioflupane 123I SPECT scans. A longer hold duration should be considered to ensure an accurate finding of dopamine deficiency."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Parkinson's Disease

Spontaneous Proximal Middle Cerebral Artery Dissection due to Stimulant-associated Vascular Injury (AAN 2026) - "Given the severity of her deficits, she received IV Tenecteplase and was transferred for thrombectomy...She was treated with IV eptifibatide and transitioned to aspirin 81 mg daily...Given her use of bupropion and Adderall, stimulant-associated vascular injury was considered... Intracranial arterial dissection (IAD) is a rare cause of stroke in the young that frequently requires angiography for diagnosis. Management remains unstandardized and necessitates broad differential consideration for underlying etiology. In our unique case, a potential cause may have been stimulant-associated vascular injury, as amphetamine derivatives have been linked to vasculopathy, vasospasm, and vessel wall injury."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • General Anxiety Disorder • Giant Cell Arteritis • Hematological Malignancies • Immunology • Ischemic stroke • Thrombosis

Brain-death Mimic, Myoclonic Seizures, and Full Recovery after Bupropion Overdose Managed With VA-ECMO and LVAD Support (AAN 2026) - "Massive bupropion overdose can mimic brain death with reversible severe neurocardiac dysfunction. Premature neuroprognostication should be avoided. Early consideration for ECMO support may improve outcomes in severe cases."

Cardiovascular • CNS Disorders • Cough • Depression • Epilepsy • Major Depressive Disorder • Mood Disorders • Respiratory Diseases • Tobacco Cessation

One in a Million: A Rare Case of Stiff Person Syndrome and its Diagnostic Challenges (AAN 2026) - "For the first three years, he was seen by three neurologists, remained undiagnosed and was symptomatically treated with duloxetine, bupropion, lamotrigine, gabapentin, baclofen, meloxicam, modafinil, and dextroamphetamine with minimal to no improvement in his symptoms. Approximately 80-98% of patients with SPS are seropositive for anti-GAD65, typically at high titers (usually >10,000IU/ml), of which over 85% have intrathecal antibodies. This case study highlights the diagnostic challenge of SPS, particularly in patients with overlapping symptoms and low antibody titers."

Clinical • CNS Disorders • Diabetes • Dysphonia • Immunology • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Neuralgia • Orthopedics • Type 1 Diabetes Mellitus

Marked Improvement in Treatment-Intolerant Obsessive-Compulsive Disorder in an Adolescent Using a Glutamatergic Regimen With Dextromethorphan, Piracetam, and Goldenseal Root. (PubMed, Cureus) - "A 16-year-old boy with severe obsessive-compulsive disorder (OCD), characterized by health-focused obsessions, intrusive ruminations, derealization, and significant functional impairment, failed to tolerate standard serotonergic agents (escitalopram, fluoxetine) and bupropion due to worsening anxiety, somatic concerns, or headaches. An oral glutamatergic regimen was initiated with dextromethorphan 30 mg/day for N-methyl-D-aspartate (NMDA) antagonism, piracetam 1,200 mg/day for AMPA modulation, and goldenseal (Hydrastis canadensis) root extract 600 mg/day as a botanical CYP2D6 inhibitor to prolong dextromethorphan exposure, alongside low-dose pregabalin, risperidone, and aripiprazole for ancillary support...These benefits lasted for two months, and there were no negative effects from goldenseal. This case indicates that a cost-effective, entirely oral amalgamation of a prevalent cough suppressant, a nootropic, and a botanical supplement may yield ketamine-like..."

Journal • CNS Disorders • Cough • Mood Disorders • Obsessive-Compulsive Disorder • Pain • Psychiatry • Respiratory Diseases

Reversible Cardiogenic Shock From Bupropion Overdose Managed With VA-to-VV ECMO Transition (ATS 2026) - No abstract available

Cardiovascular

Serum Concentration-Dependent Inhibition of CYP2D6 by Bupropion and Doxepin: Implications for Venlafaxine and Risperidone Metabolism. (PubMed, Pharmacopsychiatry) - "These effects and a phenoconversion into poor metabolizer status were detectable at subtherapeutic hydroxybupropion and therapeutic antidepressant doxepin levels. Monitoring inhibitor and victim-drug concentrations may aid in managing clinically relevant CYP2D6-mediated interactions."

Journal

Understanding Nicotine Addiction: Personalizing Therapy for Smoking Cessation. (PubMed, Cardiol Rev) - "There are 3 first-line therapies designed for smoking cessation in combination with behavioral support; these include nicotine replacement therapy, varenicline, and bupropion. In response to this major challenge, there is an ongoing search for alternative therapies. The focus of this review is on cytisine, a smoking cessation aid widely used in eastern and central Europe as an additional tool for healthcare providers."

Journal • CNS Disorders • Nicotine Addiction • Psychiatry • Tobacco Cessation